[go: up one dir, main page]

WO2001037874A3 - Treatment of psoriasis by using an antibody to tnf alpha - Google Patents

Treatment of psoriasis by using an antibody to tnf alpha Download PDF

Info

Publication number
WO2001037874A3
WO2001037874A3 PCT/US2000/042161 US0042161W WO0137874A3 WO 2001037874 A3 WO2001037874 A3 WO 2001037874A3 US 0042161 W US0042161 W US 0042161W WO 0137874 A3 WO0137874 A3 WO 0137874A3
Authority
WO
WIPO (PCT)
Prior art keywords
psoriasis
treatment
antibody
tnf alpha
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/042161
Other languages
French (fr)
Other versions
WO2001037874A2 (en
Inventor
David J Shealy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Priority to AU30824/01A priority Critical patent/AU3082401A/en
Publication of WO2001037874A2 publication Critical patent/WO2001037874A2/en
Publication of WO2001037874A3 publication Critical patent/WO2001037874A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides for uses of an anti-TNFα antibody or an antigen-binding fragment thereof for the manufacture of a medicament for use in the treatment of psoriasis or psoriatic skin lesions in an individual in need thereof.
PCT/US2000/042161 1999-11-24 2000-11-15 Treatment of psoriasis by using an antibody to tnf alpha Ceased WO2001037874A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU30824/01A AU3082401A (en) 1999-11-24 2000-11-15 Therapy of psoriasis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16747099P 1999-11-24 1999-11-24
US60/167,470 1999-11-24

Publications (2)

Publication Number Publication Date
WO2001037874A2 WO2001037874A2 (en) 2001-05-31
WO2001037874A3 true WO2001037874A3 (en) 2002-01-10

Family

ID=22607484

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/042161 Ceased WO2001037874A2 (en) 1999-11-24 2000-11-15 Treatment of psoriasis by using an antibody to tnf alpha

Country Status (2)

Country Link
AU (1) AU3082401A (en)
WO (1) WO2001037874A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285269B2 (en) 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
US8906373B2 (en) 2002-07-19 2014-12-09 Abbvie Biotechnology Ltd. Use of TNF-alpha inhibitor for treatment of psoriasis
US8961974B2 (en) 2004-04-09 2015-02-24 Abbvie Biotechnology Ltd. Multiple-variable dose regimen for treating TNFα-related disorders
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030206898A1 (en) * 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
CN101745112A (en) * 2002-07-19 2010-06-23 艾博特生物技术有限公司 Treatment of TNFalpha related disorders
US10080779B2 (en) 2004-12-15 2018-09-25 Universite D'angers Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM
EP1671642A1 (en) * 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
EP2666472A3 (en) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriatic arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP4261222A4 (en) 2020-12-09 2024-12-25 HK inno.N Corporation ANTI-OX40L ANTIBODY, ANTI-OX40L/ANTI-TNFalpha BISPECIFIC ANTIBODY, AND USES THEREOF

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001472A1 (en) * 1990-07-19 1992-02-06 Celltech Limited Multivalent anti-cytokine immunoglobulins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001472A1 (en) * 1990-07-19 1992-02-06 Celltech Limited Multivalent anti-cytokine immunoglobulins

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
C. ANTONI ET AL.: "Successful treatment of psoriatic arthritis with infliximab in a MRI controlled study", JOURNAL OF RHEUMATOLOGY, vol. 27, no. suppl. 59, August 2000 (2000-08-01), Toronto, Canada, pages 24, XP000990586 *
C. ANTONI ET AL.: "Successful treatment of severe psoriatic arthritis with infliximab.", ARTHRITIS & RHEUMATISM, vol. 42, September 1999 (1999-09-01), New York, NY, USA, pages S371, XP002165648 *
C. BONIFATI ET AL.: "Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients - relationships with disease severity.", CLINICAL AND EXPERIMENTAL DERMATOLOGY, vol. 19, no. 5, September 1994 (1994-09-01), Oxford, GB, pages 383 - 387, XP000990570 *
C. OH ET AL.: "Treatment with anti-tumor necrosis factor alpha (TNF alpha) monoclonal antibody dramatically decreases the clinical activity of psoriatis lesions.", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, vol. 42, no. 5 part 1, May 2000 (2000-05-01), St. Louis, MO, USA, pages 829 - 830, XP000990581 *
F. BAERT ET AL.: "Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis", GASTROENTEROLOGY, vol. 116, no. 1, January 1999 (1999-01-01), New York, NY, USA, pages 22 - 28, XP002165649 *
K. MACE ET AL.: "Pharmacodynamics of cA2: implications for immunotherapy.", EUROPEAN CYTOKINE NETWORK, vol. 7, no. 2, April 1996 (1996-04-01), Montrouge, pages 308, XP000990601 *
M. FELDMANN ET AL.: "TNFalpha is an effective therapeutic target for rheumatoid arthritis.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 766, 1995, New York, NY, USA, pages 272 - 278, XP000990602 *
P. ETTEHADI ET AL.: "Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions.", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 96, no. 1, April 1994 (1994-04-01), Oxford, GB, pages 146 - 151, XP000990589 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906373B2 (en) 2002-07-19 2014-12-09 Abbvie Biotechnology Ltd. Use of TNF-alpha inhibitor for treatment of psoriasis
US7285269B2 (en) 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
US8961974B2 (en) 2004-04-09 2015-02-24 Abbvie Biotechnology Ltd. Multiple-variable dose regimen for treating TNFα-related disorders
US8961973B2 (en) 2004-04-09 2015-02-24 Abbvie Biotechnology Ltd. Multiple-variable dose regimen for treating TNFα-related disorders
US8986693B1 (en) 2004-04-09 2015-03-24 Abbvie Biotechnology Ltd. Use of TNFα inhibitor for treatment of psoriasis
US9187559B2 (en) 2004-04-09 2015-11-17 Abbvie Biotechnology Ltd Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease
US9499615B2 (en) 2004-04-09 2016-11-22 Abbvie Biotechnology Ltd Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease
US9512216B2 (en) 2004-04-09 2016-12-06 Abbvie Biotechnology Ltd. Use of TNFα inhibitor
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
US9284370B1 (en) 2007-06-11 2016-03-15 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis

Also Published As

Publication number Publication date
WO2001037874A2 (en) 2001-05-31
AU3082401A (en) 2001-06-04

Similar Documents

Publication Publication Date Title
FI963101L (en) Use of anti-TNF antibodies as a drug for the treatment of diseases in which serum interleukin-6 levels are elevated
WO1997017446A3 (en) HUMANIZED ANTIBODIES TO HUMAN gp39, COMPOSITIONS CONTAINING AND THERAPEUTIC USE THEREOF
BG107537A (en) INHIBITION OF HUMAN TNF ALPHA ACTIVITY
WO2005062972A3 (en) Treatment of cancer with novel anti-il 13 monoclonal antibodies
WO2002074337A8 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
NO20031218L (en) Combination therapy for the treatment of autoimmune diseases using B-cell-reducing immunoregulatory antibody combination
HUS1600042I1 (en) Therapeutic use of anti-CS1 antibodies
WO2001037874A3 (en) Treatment of psoriasis by using an antibody to tnf alpha
IT9068053A0 (en) PREPARATION INCLUDING BIOTINYLATED MONOCLONAL ANTIBODIES, AVIDIN AND BIOTIN, FOR THE DIAGNOSIS AND THERAPY OF CANCER DISEASES AND ITS USE
AU2003248245A1 (en) Remedies for diseases caused by vascular contraction or dilation
DK0730864T3 (en) Medication for the treatment of inflammatory heart disease
IL113873A0 (en) Novel uses of triplex forming oligonucleotides for the treatment of human diseases
WO2004094473A3 (en) Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
DE60045240D1 (en) ANTIBODIES TO TNF ALPHA FOR THE THERAPY OF STEROID-RESISTANT ASTHMA
WO2001051044A3 (en) Substances for use in treating psoriasis
WO2003097082A3 (en) Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
AU2003303217A1 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
EE9900010A (en) Therapeutic applications of T-BAM (CD40L) technology for the treatment of smooth muscle cell related diseases
WO1996040041A3 (en) Antibodies to fas antigen capable of inhibiting apoptosis
IT1233005B (en) MONOCLONAL HUMAN ANTIBODY, THERAPEUTIC COMPOSITION THAT CONTAINS IT MOBILE LINE ABLE TO PRODUCE THE ANTIBODY, PROCEDURE FOR ITS PRODUCTION
AU2001280256A1 (en) Methods for the diagnosis and/or treatment of diseases related to anti-phospholipid antibodies and devices used therein
AU2003295504A1 (en) Development of therapeutics for the treatment of endotoxin-mediated diseases
IT8821369A0 (en) PHARMACEUTICAL COMPOSITION USEFUL FOR THE TREATMENT OF CARDIOVASCULAR DISEASES.
WO2001075010A3 (en) A novel polypeptide, human nuclear transduction protein 25 containing a structural atp/gtp domain
WO2001075054A3 (en) A novel polypeptide, microglobulin transcription human regulation factor 30 and the polynucleotide encoding the polypeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase